Real-World study reveals omalizumab dosing patterns for chronic hives in china
NCT ID NCT07450170
First seen Mar 17, 2026 · Last updated May 12, 2026 · Updated 10 times
Summary
This study examined how the drug omalizumab is prescribed to adults with chronic urticaria (long-term hives) in China. Researchers analyzed electronic health records from 3,485 patients to see which doses were most common. The goal was to understand real-world treatment patterns, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC URTICARIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis
Shanghai, 201203, China
Conditions
Explore the condition pages connected to this study.